| Disease | PARTICIPANTS WHO RECEIVED 180 MG OF GINKGO BILOBA EXTRACT 761 DAILY FOR 6 WEEKS EXHIBITED SIGNIFICANTLY MORE IMPROVEMENT ON A TASK ASSESSING SPEED OF PROCESSING ABILITIES (I.E., STROOP COLOR AND WORD TEST COLOR-NAMING TASK) BY THE END OF
TREATMENT AS COMPARED TO PARTICIPANTS WHO RECEIVED PLACEBO. TRENDS FAVORING IMPROVED PERFORMANCES IN THE GINKGO BILOBA GROUP WERE ALSO DEMONSTRATED IN THREE OF THE FOUR REMAINING TASKS THAT INVOLVED A TIMED, SPEED OF PROCESSIGN COMPONENT,
ALTHOUGH THEY DID NOT REACH STATISTICAL SIGNIFICANCE. FURTHERMORE, A SIGNIFICANT RELATIONSHIP WAS FOUND BETWEEN THE TYPE OF TREATMENT (GINKGO BILOBA EXTRACT OR PLACEBO) AND PARTICIPANTS' RATINGS OF THEIR OVERALL ABILITIES TO REMEMBER.
SPECIFICALLY, MORE PARTICIPANTS IN THE GINKGO BILOBA EXTACT GROUP RATED THEIR OVERALL ABILITIES TO REMEMBER BY THE END OF TREATMENT AS "IMPROVED," AS COMPARED TO THE PLACEBO GROUP. IN CONTRAST, NO SIGNIFICANT DIFFERENCES WERE FOUND BETWEEN THE
GINKGO BILOBA AND PLACEBO GROUPS BY TREATMENT END ON ANY OF THE FOUR OBJECTIVE MEMORY MEASURES. TAKEN TOGETHER, THE FINDINGS FROM STANDARDIZED NEUROPSYCHOLOGIC ASSESSMENT AND A SUBJECTIVE, SELF-REPORT QUESTIONNAIRE SUGGESTED THAT RELATIVELY
SHORT-TERM (I.E., 6 WEEKS) UTILIZATION OF GINKGO BILOBA EXTRACT EGB 761 MAY PROVE EFFICACIOUS IN ENHANCING CERTAIN NEUROCOGNITIVE FUNCTIONS/PROCESSES OF COGNITIVELY INTACT OLDER ADULTS. |